MusclePharm Corporation (OTCBB:MSLP) is one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in its portfolio of performance products.
Muscle Pharm Corp. top management has extensive experience in the sports world and has harnessed this drive and focus into building a business to benefit its customers and help Fuel The Athlete Inside™.
UFC star Jake Shields was wearing MSLP apparel at the UFC 121 co-main event and got the job done as he won the split decision over Martin Kampmann at UFC 121. The judges saw the fight 28-29, 30-27, 29-28 for Shields.
Each and every MusclePharm product is the end result of an advanced six-stage research and testing protocol involving the expertise of top nutrition scientists. In addition, the products have been field-tested by more than 100 elite professional athletes from the NFL, MMA, MLB and elsewhere.
Furthermore, MSLP previously entered into a distribution agreement with TapouT to launch a MusclePharm apparel line that includes t-shirts, sweat suits, shorts and other active wear items.
Also, Bodybuilding.com previously selected the Company as the Supplement Company of the Month for October.Bodybuilding.com recognizes leading supplement companies with products and services that are making a positive impact on the industry and their consumers each month.
For more information about this company please visit http://www.musclepharm.com
Power3 Medical Products, Inc. (OTC:PWRM) Power3 Medical Products, Inc. has recently signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc., a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy.
Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials.
The tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
PWRM plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into PWRM, with PWRM remaining as the surviving company in the merger.
Power3 Medical is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.
For more information about this company please visit http://www.power3medical.com
Lazard Ltd (NYSE:LAZ) recently has hired Youngbum Kwon as a Managing Director and Head of Korean Investment Banking, effective immediately.
Based in Seoul, Mr. Kwon joined Lazard from Deutsche Bank, where he was a Managing Director and Head of M&A for Korea, Hong Kong and Taiwan.
Ensco plc (NYSE:ESV) recently reported diluted earnings per share from continuing operations of $0.92 for third quarter 2010, compared to $1.01 per share in third quarter 2009.
Pactiv Corporation (NYSE:PTV), a leader in the consumer and foodservice packaging markets, announced recently that it commenced its offer to purchase for cash any and all of its outstanding 5.875% Notes due 2012 (the “2012 Notes”), at a price of 101% of the principal amount of such 2012 Notes, plus accrued and unpaid interest on the principal amount tendered to, but not including, the payment date.
The change of control offer is being conducted in connection with the pending merger transaction of Pactiv with Reynolds Group Holdings Limited
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. The fee may be in cash, in free trading stock, in restricted stock, or in any combination thereof. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings, Inc. (OTCPK:CRWE) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (OTCQB:MSLP). Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).